A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

FDA Approves New-Age NON-OPIOID Pain Relief Formula That Does NOT Shut Down Your Vital Organs Via Heroin Addiction. NEWS ...

CHATHAM, NJ / ACCESS Newswire / March 31, 2025 / This post was written and published as a collaboration between the in-house ...

FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve clinical outcomes and QOL.

The following is a summary of “Suzetrigine, a Non-Opioid NaV1.8 Inhibitor With Broad Applicability for Moderate-to-Severe Acute Pain: A Phase 3 Single-Arm Study for Surgical or Non-Surgical Acute Pain ...

The FDA’s landmark approval of Journavx (suzetrigine)—the first non-opioid pain reliever in over two decades—represents a breakthrough in pain management. This breakthrough underscores the ...

LONG BEACH, Calif., March 19, 2025--(BUSINESS WIRE)--The FDA’s landmark approval of Journavx (suzetrigine)—the first non-opioid pain reliever in over two decades—represents a breakthrough in ...

LONG BEACH, Calif.--(BUSINESS WIRE)--#CNSresearch--The FDA’s landmark approval of Journavx (suzetrigine)—the first non-opioid pain reliever in over two decades—represents a breakthrough in pain ...

The FDA’s Vaccines and Related Biological Products Advisory Committee had been scheduled to meet Thursday to weigh in on the composition of the flu shots, but that session was canceled without ...

The U.S. Food and Drug Administration’s (FDA) chief counsel resigned two days after her appointment, according to a Thursday announcement from the agency. “Hilary K. Perkins has resigned from ...

“The FDA approval of suzetrigine (Journavx) opens the door to a new class of oral systemic medications for patients who suffer from acute pain, including pain after surgery,” says Dr. Edward ...